Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02996669 · ClinicalTrials.gov registry record
Autism Biomarker Consortium for Clinical Trials
A clinical trial of Autism Spectrum Disorder, sponsored by Yale University.
- Completed
- Registry status
- 399
- Enrollment target
- 1
- Study location
NCT02996669: Completed study of Autism Spectrum Disorder, sponsored by Yale University.
NCT02996669 is a study of Autism Spectrum Disorder that has completed, run by Yale University. The registered enrollment target is 399 participants, above the 134-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (198% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02996669, a study of Autism Spectrum Disorder, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 399 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multicenter longitudinal study that aims to identify, develop and validate a set of measures that can be used as stratification biomarkers and/or sensitive and reliable objective measures of social impairment in autism spectrum disorders (ASD) that could serve as markers of long term clinical outcome. The main study will include 275 individuals: 200 ASD subjects between 6-11 years old, and 75 TD subjects roughly matched by age and sex to the ASD group.
Primary Outcome
NEPSY-II - Memory for Faces Subtest (administered to all ages): The NEPSY-II Memory for Faces subtest entails viewing a series of faces and having the child identify the sex of each face. The child is then shown three faces at a time and required to identify the previously seen face.
Conditions Studied
Study Locations (1)
Connecticut
- Yale University Child Study Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 399 participants |
| Start Date | 2016-10 |
| Est. Completion | 2019-05-13 |
What the finished NCT02996669 record still lists
NCT02996669 is an observational study that tracks outcomes without assigning an intervention. The registered 399 participants enrollment target is mid-sized for trials with a published cap, above the 134-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (198% higher).
The record links to 1 condition, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT02996669 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT02996669 about?
NCT02996669 is a clinical study titled "Autism Biomarker Consortium for Clinical Trials". This is a multicenter longitudinal study that aims to identify, develop and validate a set of measures that can be used as stratification biomarkers and/or sensitive and reliable objective measures of social impairment in autism spectrum disorders (ASD) that could serve as markers of long term clini...
What is the current status of trial NCT02996669?
This trial is currently completed. The enrollment target is 399 participants. The study started on 2016-10. Estimated completion is 2019-05-13.
What conditions does trial NCT02996669 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder.
Who is sponsoring clinical trial NCT02996669?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02996669 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02996669's enrollment target sits among peer trials
399 17th of 224 higher than 208 of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design
RECRUITING · Early Phase 1
-
Cannabidiol (CBD) in Adults With ASD
RECRUITING · Phase 1
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Emergent Multi-Class Imitation Training
RECRUITING · NA
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03165734 · 399 participants · Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- NCT05022862 · 399 participants · NA
Economic Incentives and vDOT for Latent Tuberculosis Infection
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia